Wider cost benefits of vaccine

摘要

The FUTURE Study Group's results confirm the benefit to women of vaccinating against human papillomavirus (HPV) types 16 and 18 and emphasise the value of including HPV-6 and HPV-11 in any vaccine programme. HPV-6 and HPV-11 cause almost all condylomatas and a large proportion of cases of low grade vulval, vaginal, and cervical intraepithelial neoplasia. The management of genital warts in women is expensive-estimates varied from ￡160 (european dollow195; $250) in one recent study to ￡300 in a prospective study.that looked at staff and pharmacy costs only.